A busy hospital floor (L) and a 3D illustration of a nerve cell being attacked by antibodies (R).

...

Melissa Fleur Afshar

By Melissa Fleur Afshar

Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


CAR‑T cell therapy, a cutting‑edge cancer treatment, is showing growing promise far beyond oncology—offering potential relief to people with severe autoimmune diseases who have exhausted other options.

“In simple terms, CAR T‑cell therapy is a form of treatment that uses a person’s own immune cells to attack and kill their cancer cells,” Dr. Vinod Balasa, medical director of Valley Children’s Cancer and Blood Disorders Center, told Newsweek. “While chemotherapy uses a shotgun approach that can impact normal cells while it kills cancer cells, CAR T‑cell therapy is a targeted treatment.”

Originally developed to treat certain blood cancers, CAR‑T therapy is now being tested against autoimmune diseases that are driven by malfunctioning immune cells. Early results suggest it may be capable of putting some patients into long‑lasting remission, even after years of failed treatment.

Read More on Health

One Woman’s Recent Experience

By the time hematologist‑oncologist Fabian Müller met a critically ill patient at the center of his latest research, he believed the experimental therapy might be her final option. The 47-year-old woman had spent years battling three severe autoimmune diseases that caused her body to attack key components of her blood.

Despite nine prior treatment attempts, her conditions remained uncontrolled. By early 2025, the mother of two had been hospitalized in Dresden, Germany, for more than two months. Doctors administered multiple immunosuppressive drugs and up to three daily red blood cell transfusions as they tried to manage a massive disease flare—without success.

In desperation, her care team contacted Müller at the University Hospital of Erlangen, roughly three hours away from the Dresden hospital. Müller and his colleagues have gained international attention for pioneering experimental CAR‑T cell therapies for autoimmune diseases, building on technology first developed for cancer.

The patient ultimately received CAR‑T treatment under compassionate‑use criteria. Following therapy, she returned to a largely normal life—a result Müller hopes will prove durable over time.

Resetting a Faulty Immune System

The woman suffered from autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid antibody syndrome (APLAS). These are all B‑cell‑driven diseases, meaning they are caused by immune cells producing harmful antibodies that attack the body’s own tissues.

CAR‑T therapy targets this malfunction. The process involves collecting a patient’s own immune cells and genetically engineering them to recognize CD19, a marker found on B cells. These altered cells are then reinfused, where they seek out and eliminate the dysfunctional B cells.

A busy hospital floor (L) and a 3D illustration of a nerve cell being attacked by antibodies (R).

...

In this case, the patient had both cold‑ and warm‑agglutinin AIHA that was life‑threatening and resistant to nine prior lines of therapy. She first underwent lymphodepleting chemotherapy, followed by an infusion of CD19‑directed CAR‑T cells.

Researchers tracked her response over an 11‑month follow‑up period. They reported rapid and durable remission of her severe AIHA, along with improvement in her co‑existing ITP and APLAS.

Small studies and early results from ongoing trials suggest many autoimmune patients treated with CAR‑T therapy go into remission, with some remaining disease‑free for years without additional care. However, researchers stress that broader, controlled clinical trials are still needed.

“These therapies are some of the most powerful weapons we have in our cancer‑fighting arsenal,” Balasa said. “But they also require a combination of medical expertise and specialized equipment to deliver effectively.”

Do you have a tip on a health story that Newsweek should be covering? Do you have a question about autoimmune disease? Let us know via health@newsweek.com.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines